Breaking News

Fresenius Kabi’s NY Facility Gets FDA Status Upgrade

New VAI classification permits FDA approval of new products

Fresenius Kabi’s pharmaceutical manufacturing facility in Grand Island, NY, has achieved the upgraded status of voluntary action indicated (VAI) from the U.S. FDA following an October 2014 inspection. The facility previously operated under “official action indicated” status. The new VAI classification permits FDA approval of new Fresenius Kabi products at the plant.
 
The status change reflects improvements made at the plant since receiving a warning letter in 2012.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters